Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simon, S. L. R.
Right arrow Articles by Murphy, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simon, S. L. R.
Right arrow Articles by Murphy, L. C.
[Cancer Research 60, 2796-2799, June 1, 2000]
© 2000 American Association for Cancer Research


Advances in Brief

Expression of a Repressor of Estrogen Receptor Activity in Human Breast Tumors: Relationship to Some Known Prognostic Markers1

Sharon L. R. Simon, Alicia Parkes, Etienne Leygue, Helmut Dotzlaw, Linda Snell, Sandra Troup, Adewale Adeyinka, Peter H. Watson and Leigh C. Murphy2

Departments of Biochemistry and Medical Genetics [S. L. R. S., A. P., E. L., H. D., L. C. M.] and Pathology [L. S., S. T., A. A., P. H. W.], Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0W3, Canada

The expression of a specific repressor of estrogen receptor activity (REA) was investigated by a semiquantitative reverse transcription-PCR assay in 40 human breast tumor biopsy samples with respect to steroid hormone receptor status and other known prognostic variables. The data showed that REA expression was positively correlated with estrogen receptor (ER) levels as defined by ligand-binding assays (Spearman r = 0.3231; P = 0.042) and that the median level of REA mRNA was significantly (Mann-Whitney two-tailed test, P = 0.0424) higher in ER+ tumors (median = 94.5; n = 30) compared with ER- tumors (median = 64.5; n = 10), with no significant differences (P = 0.4988) associated with progesterone receptor status alone. In addition, REA expression was inversely correlated with tumor grade (Spearman r = -0.4375; P = 0.0054). When the tumors were divided into two groups based on grade, REA expression was significantly (Mann-Whitney two-tailed test, P = 0.0024) higher in low-grade (median = 97; n = 16) compared with high-grade (median = 76; n = 23) tumors. These results provide preliminary data suggesting that the expression of REA varies among breast tumors and is correlated with known treatment response markers and inversely correlated with a marker of breast cancer progression. REA together with ER status may be an improved marker of endocrine therapy responsiveness in human breast cancer.




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al.
Estrogen Receptors: How Do They Signal and What Are Their Targets
Physiol Rev, July 1, 2007; 87(3): 905 - 931.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Mussi, L. Liao, S.-E. Park, P. Ciana, A. Maggi, B. S. Katzenellenbogen, J. Xu, and B. W. O'Malley
Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland
PNAS, November 7, 2006; 103(45): 16716 - 16721.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al.
Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy
Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Kumar, A. E. Gururaj, R. K. Vadlamudi, and S. K. Rayala
The Clinical Relevance of Steroid Hormone Receptor Corepressors
Clin. Cancer Res., April 15, 2005; 11(8): 2822 - 2831.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S.-E. Park, J. Xu, A. Frolova, L. Liao, B. W. O'Malley, and B. S. Katzenellenbogen
Genetic Deletion of the Repressor of Estrogen Receptor Activity (REA) Enhances the Response to Estrogen in Target Tissues In Vivo
Mol. Cell. Biol., March 1, 2005; 25(5): 1989 - 1999.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. H. Herynk and S. A. W. Fuqua
Estrogen Receptor Mutations in Human Disease
Endocr. Rev., December 1, 2004; 25(6): 869 - 898.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Y. Lin, E. M. Resnick, and M. A. Shupnik
Truncated Estrogen Receptor Product-1 Stimulates Estrogen Receptor {alpha} Transcriptional Activity by Titration of Repressor Proteins
J. Biol. Chem., October 3, 2003; 278(40): 38125 - 38131.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.